These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 31085272)

  • 1. The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review.
    Pham CT; Juhasz M; Sung CT; Mesinkovska NA
    J Am Acad Dermatol; 2020 Jan; 82(1):202-212. PubMed ID: 31085272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
    Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
    BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV and HPV-associated diseases.
    Dunne EF; Park IU
    Infect Dis Clin North Am; 2013 Dec; 27(4):765-78. PubMed ID: 24275269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
    McCormack PL
    Drugs; 2014 Jul; 74(11):1253-83. PubMed ID: 25022951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chapter 17: Genital human papillomavirus infections--current and prospective therapies.
    Stanley M
    J Natl Cancer Inst Monogr; 2003; (31):117-24. PubMed ID: 12807955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
    Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
    PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
    Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
    Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
    Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
    Arbyn M; de Sanjosé S; Saraiya M; Sideri M; Palefsky J; Lacey C; Gillison M; Bruni L; Ronco G; Wentzensen N; Brotherton J; Qiao YL; Denny L; Bornstein J; Abramowitz L; Giuliano A; Tommasino M; Monsonego J
    Int J Cancer; 2012 Nov; 131(9):1969-82. PubMed ID: 22623137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HR-HPV E6/E7 mRNA In Situ Hybridization: Validation Against PCR, DNA In Situ Hybridization, and p16 Immunohistochemistry in 102 Samples of Cervical, Vulvar, Anal, and Head and Neck Neoplasia.
    Mills AM; Dirks DC; Poulter MD; Mills SE; Stoler MH
    Am J Surg Pathol; 2017 May; 41(5):607-615. PubMed ID: 28403015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L; Hopkins L; Hutton B; Fergusson D
    CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.
    Sanclemente G; Herrera S; Tyring SK; Rady PL; Zuleta JJ; Correa LA; He Q; Wolff JC
    J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1054-60. PubMed ID: 17714124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
    Palefsky JM; Giuliano AR; Goldstone S; Moreira ED; Aranda C; Jessen H; Hillman R; Ferris D; Coutlee F; Stoler MH; Marshall JB; Radley D; Vuocolo S; Haupt RM; Guris D; Garner EI
    N Engl J Med; 2011 Oct; 365(17):1576-85. PubMed ID: 22029979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV-related squamous neoplasia of the lower anogenital tract: an update and review of recent guidelines.
    Maniar KP; Nayar R
    Adv Anat Pathol; 2014 Sep; 21(5):341-58. PubMed ID: 25105936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.